- Conditions
- Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
- Interventions
- Cisplatin, Methoxyamine, Pemetrexed Disodium
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Pasadena, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 625
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- pembrolizumab, pemetrexed, carboplatin, cisplatin, saline solution
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 492 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Monterey, California • Orange, California + 14 more
- Conditions
- Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- erlotinib hydrochloride, pemetrexed disodium
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 5
- States / cities
- Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more
- Conditions
- Resectable Non-small Cell Lung Cancer
- Interventions
- Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Clermont, Florida • Chicago, Illinois • Westwood, Kansas + 5 more
- Conditions
- Adenocarcinoma of Lung, Lung Cancer
- Interventions
- Oral Restorative Microbiota Therapy (RMT) Capsules, Durvalumab 1500 mg IV, Cisplatin/pemetrexed or Carboplatin/pemetrexed, Placebo
- Drug · Other
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Brainerd, Minnesota • Deer River, Minnesota + 7 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- LY2603618, Pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Denver, Colorado • Tampa, Florida + 6 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- TG4010, placebo
- Biological · Drug
- Lead sponsor
- Transgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Topeka, Kansas • Louisville, Kentucky + 9 more
- Conditions
- Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local
- Interventions
- Avastin (bevacizumab), Tarceva (erlotinib HCl)
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 48
- States / cities
- Bakersfield, California • Concord, California • Fullerton, California + 40 more
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- paclitaxel poliglumex, pemetrexed
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- GEN1042, Pembrolizumab, Cisplatin, Carboplatin, 5-FU, Gemcitabine, Nab paclitaxel, Pemetrexed, Paclitaxel
- Biological · Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 23
- States / cities
- Anchorage, Alaska • Los Alamitos, California • San Diego, California + 19 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Calderasib, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Farmington, Connecticut • Stamford, Connecticut + 12 more
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pembrolizumab, Filgrastim, Pegylated filgrastim
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Clermont, Florida • Orange City, Florida + 6 more
- Conditions
- Solid Tumors
- Interventions
- MM-121, Carboplatin, Pemetrexed, Cabazitaxel, Gemcitabine
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Lafayette, Indiana • Buffalo, New York • Cincinnati, Ohio + 1 more
- Conditions
- Lung Cancer
- Interventions
- Afatinib, Radiation, Cisplatin, Pemetrexed, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Carboplatin, Paclitaxel, Ramucirumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant Mesothelioma
- Interventions
- Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 13
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 10 more
- Conditions
- Metastatic NSCLC
- Interventions
- GME751, Keytruda-EU
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Fountain Valley, California
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Interventions
- Cisplatin, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Therapeutic Conventional Surgery
- Drug · Biological · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Arm A: Pemetrexed Cisplatin, Arm B Pemetrexed, Cisplatin and MK-0646
- Drug
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 4
- States / cities
- Hutchinson, Kansas • Kansas City, Kansas • Topeka, Kansas + 1 more
- Conditions
- Recurrent Non-small Cell Lung Cancer
- Interventions
- cediranib maleate, pemetrexed disodium
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Detroit, Michigan
- Conditions
- Lung Cancer
- Interventions
- Paclitaxel, Carboplatin, Bevacizumab, Pemetrexed Disodium Heptahydrate
- Drug · Biological
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 434
- States / cities
- Anniston, Alabama • Fairbanks, Alaska • Fairfield, California + 312 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Pemetrexed, Cisplatin, Cixutumumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Hackensack, New Jersey • Portland, Oregon + 2 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- eribulin mesylate, pemetrexed, Eribulin mesylate (eribulin; E7389)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Denver, Colorado • Fort Myers, Florida + 3 more